Emerging EPO and EPO receptor regulators and signal transducers

David Kuhrt1 and Don M. Wojchowski1,2

1Molecular Medicine Division, Maine Medical Center Research Institute, Scarborough, ME; and 2Tufts University School of Medicine, Boston, MA

As essential mediators of red cell production, erythropoietin (EPO) and its cell surface receptor (EPO receptor [EPOR]) have been intensely studied. Early investigations defined basic mechanisms for hypoxia-inducible factor induction of EPO expression, and within erythroid progenitors EPOR engagement of canonical Janus kinase 2/signal transducer and activator of transcription 5 (JAK2/STAT5), rat sarcoma/mitogen-activated protein kinase/extracellular signal-regulated kinase (RAS/MEK/ERK), and phosphatidylinositol 3-kinase (PI3K) pathways. Contemporary genetic, bioinformatic, and proteomic approaches continue to uncover new clinically relevant modulators of EPO and EPOR expression, and EPO's biological effects. This Spotlight review highlights such factors and their emerging roles during erythropoiesis and anemia. (Blood. 2015;125(23):3536-3541)

Introduction

Early parabiotic experiments with anemic and nephrectomized rats predicted the existence of erythropoietin (EPO) as a blood-borne kidney-derived activator of erythropoiesis. Evidence that EPO occurs as a unique glycoprotein hormone was further advanced via arduous fractionations and bioassays of urinary proteins from anemia patients.2 The purification, partial sequencing, and cloning of erythropoietin3 have led to the generation of recombinant human EPO (rhEPO) (and derivatives) for the treatment of anemia associated with chronic kidney disease, chemotherapy, and low-risk myelodysplastic syndrome. The subsequent discovery of the EPO receptor (EPOR) as a plasma membrane single-pass homodimer4,6 elevated the EPO/EPOR system as a paradigm for hematopoietic cytokine receptor action. The EPOR, for example, was among the first discovered to associate with a Janus kinase (JAK),7 to transduce signals via transmembrane conformational mechanisms,8 and to be causally associated with polycythemia.9 EPO’s clinical and scientific successes have prompted in-depth investigations into EPO/EPOR biology. This review focuses on intriguing advances in understanding the regulation of EPO and EPOR expression, and the nature of novel EPO/EPOR signals that regulate erythroid progenitor cell (EPC) development. EPO also has been reported to exert survival, proliferative, and/or developmental effects in a wide range of nonhematopoietic tissues.10-16 In such cell types, however, EPOR protein expression (including cell surface levels) can be nominal,13 thereby complicating interpretations for direct vs indirect effects. Nonetheless, incisive EPOR loss-of-function approaches have revealed interesting EPO effects in cardiomyocyte mitochondrial biogenesis,18 retinal cell cytoprotection,19 melanoma cell survival,20 and adipogenesis.21 This broad area of investigation, however, lies beyond the scope of the present report.

EPO expression

The nature of rare Epo-producing cells is first becoming more clearly defined. During primitive erythropoiesis, studies using an Epo gene green fluorescent protein knock-in mouse indicate predominant Epo expression by neural crest and neuroepithelial cells.22 Tracking studies of myelin protein-zero23 marked peripheral neural cells demonstrate that Epoembryonic neural crest fibroblasts migrate to the kidney,24 and perinatally reside within peritubular interstitia.25 Renal fibrosis due to ureteral obstruction can promote transdifferentiation of Epon high fibroblasts to Epo low myofibroblasts.26 Epo levels in myofibroblasts can be increased, however, via neurotropin or dexamethasone dosing. During stress erythropoiesis, Epo expression can also be induced in the liver,26 as well as bone marrow (BM) osteoblasts as demonstrated upon von Hippel–Lindau factor (VHL) inactivation.27 New insight has also been gained into EPO gene regulation. Early investigations of hypoxia-induced EPO expression established important roles for a downstream EPO enhancer (E-3′) as a binding site for hypoxia-inducible factor (HIF) and hepatocyte nuclear factor 4 transcriptional regulators.28 In vivo studies in mice with a green fluorescent protein-marked Epo allele demonstrate that E-3′ deletion results in embryonic and neonatal anemia.25,26 In juvenile and adult kidney, however, Epo production is unexpectedly regained in the absence of E-3′,26 whereas hepatic Epo production continues to depend upon E-3′ effects.26 For renal EPO production, this raises new questions concerning activation mechanisms. Among HIF1α, -2α, and -3α, HIF2α has been defined as a prime component of an EPO gene activating complex.29 New insight into HIF2α regulation (beyond requisite heterodimerization with HIFβ/aryl hydrocarbon receptor nuclear translocator)30 has also been gained. HIF2α’s translation first has been shown to be suppressed via iron response element binding protein 1 (Irp1) (in a knockout [KO] mouse model), thus connecting iron levels to Hif2α/HIFβ-regulated Epo gene expression.31 HIF2α’s activity is also modulated by lysine acetylation and deacetylation via CREB-binding protein (CBP) and sirtuin, respectively.32 For acetylation, acetyl-CoA levels during stress erythropoiesis can become physiologically limiting. Specifically, Hif2α’s acetylation, CBP association, and enhanced activity have been shown in an Acss2-KO model to depend upon acetyl-CoA synthetase-2.33 Moreover, acetate supplementation in vivo elevates Epo levels as well as hematocrits in hemolytic, partial nephrectomy chronic kidney disease, and Kit mutant models. The turnover of HIFs is promoted via hydroxylation by prolyl 4-hydroxylases (PHDs), and ubiquitination by
VHL. Notably, several PHD inhibitors have been developed as HIF stabilizers to enhance EPO and erythrocyte production (eg, roxadustat [FibroGen/Astellas], AKB-6548 [Akebia Therapeutics], and GSK1278863 [GlaxoSmithKline]).

**EPO receptor expression and EPOR signal modifiers**

The expression of EPO’s receptor is stringently regulated and is at a low level (~1100 EPORs per primary human EPC and ~300 per late-stage erythroblast) as determined via 125I-EPOR binding studies. At the EpoR locus, Gata1, Sp1, and Scl/Tal1 stimulate transcription, but additional regulators are not well defined. For EPOR trafficking, certain new insights have been gained. Over-expression studies in murine myeloid 32D cells suggest ligand-independent EpoR turnover, with replenishment from a predicted large intracellular pool. For the endogenous EPOR, however, studies in human UT7epo and/or primary EPCs demonstrate substantial up-regulation of cell surface EPORs when EPO is limited, marked down-modulation upon EPO exposure, and only modest intracellular EPOR pools. During EPOR endocytosis, coordinated roles for p85-α (PI3 kinase regulatory subunit), ubiquitinized casitas B-lineage lymphoma and Epsin1 have been described. In UT7epo cells and β-transducin repeat containing E3 ubiquitin ligase (β-TRCP) subsequently promotes EPOR degradation. Dynamic down-modulation of low-level EPOR cell surface expression emphasizes a need for cautious interpretation of apparent EPOR levels, and the use of high-specificity reagents.

Several new EPOR interacting factors have been described. Proteomic analyses of biotin-EPO/EPOR complexes have identified transferrin receptor 2 (TFR2) as an EPOR partner. In UT7epo cells, TFR2 facilitates EPOR processing and transport to the cell surface. In primary human EPCs, TFR2 knockdown decreased hemoglobinized cell formation, and increased numbers of early stage EPCs. EPCs from Tfr2−/− mice exhibit decreased EPO sensitivity and erythroid colony-forming unit formation. During iron deficiency, Tfr2 also acts to balance erythocyte production with available iron. Beyond its established roles in hepatocyte iron transport, Tfr2 also therefore modulates EPO-dependent erythropoiesis. In addition, phospho-proteomic analyses have identified the integral plasma membrane protein regulator of human erythroid cell expansion (RHEX) as a new EPOR-associated factor. In UT7epo cells, RHEX co-IP’s with EPOR/JAK2 complexes, and its tyrosine phosphorylation is strongly induced by EPO. In primary EPCs, RHEX exhibits stage-specific expression, and its knockdown attenuates extracellular signal-regulated kinase 1/2 (ERK1/2) activation as well as late-stage human erythroblast development. Interestingly, RHEX is not represented among rat, mouse, or lower vertebrates.

Transferrin receptor 1 (TFR1) can also modulate EPOR signaling. Specifically, Tfr1 ligation by polymeric-IgA1 (p-IgA1) in murine erythroblasts increases EPO/EPOR-dependent mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling. This occurs in the absence of transferrin binding, but depends upon a Tfr1 endocytic motif. In a knock-in model, human p-IgA1 enhances recovery from anemia due to 5-fluorouracil, hypoxia, and hemolytic anemia. p-IgA1 also binds CDA9, an Fc-α receptor and suppressor of inflammatory cytokine production. By speculation, p-IgA1 might also aid stress erythropoiesis by lessening inflammation, a mechanism implicated for an activin receptor-IIA ligand trap as a new anti-anemia agent.

**EPO signal transduction via rat sarcoma/mek kinase/mitogen-activated protein kinase (RAS/RAF/MEK)/ERK circuits**

As demonstrated in primary human EPCs, balanced activation of RAS pathways is required for effective EPO-dependent erythroblast formation. In mouse models, the deletion of K-Ras (but not H-Ras or N-Ras) generates severe anemia, and compromises EPO-dependent fetal liver EPC development. Activated K-Ras likewise induces severe anemia due to ineffective fetal erythropoiesis, and persistently stimulates Erk1/2, Akt, and signal transducer and activator of transcription 5 (Stat5). Of clinical interest, the inhibition of RAS farnesylation by tipifarnib decreases polyethylene-mera erythroid burst-forming unit hyperproliferation. During erythropoiesis, RAS is also regulated by newly emerging guanosine triphosphate (GTP)/guanosine diphosphate exchange factors. One is the Ras-GTPase activating protein Ras3, which when mutated in Scat mice leads to anemia and thrombocytopenia. A second is neurofibromin (Nf1), for which mutations have been associated with juvenile myelomonocytic leukemia, including anemia due to limited EPC differentiation.

Regulation of RAS-modulated targets is also important for EPO-dependent erythropoiesis. C-Raf deletion results in embryonic anemia. And in β-thalassemia proerythroblasts, phospho-C-Raf levels correlate with increased ERK activation. Mek2 is dispensable for mouse development, implicating prime roles for Mek1 in Erk1/2 signaling in mice expressing a truncated EpoR-HM allele, pharmacologic inhibition of Mek reverses stage-specific EPO differentiation defects, whereas in mice with somatic inactivation of Nf1, Mek1/2 inhibition decreases splenomegaly and enhances erythropoiesis. For ERKs, Erk1/2−/− mice exhibit heightened splenic erythropoiesis and hematocrits.

RAS-like GTPases can also regulate EPO-dependent EPC formation. As a new EPO/EPOR target gene and Roco family GTPase, malignant fibrous histiocytoma-amplified sequences with leucine-rich tandem repeats 1 (MASL1) supports C-RAF/MEK/ERK activation and primary human erythroblast development. As demonstrated in primary human EPCs, balanced activation of RAS pathways is required for effective EPO-dependent erythroblast formation. In mouse models, the deletion of K-Ras (but not H-Ras or N-Ras) generates severe anemia, and compromises EPO-dependent fetal liver EPC development. Activated K-Ras likewise induces severe anemia due to ineffective fetal erythropoiesis, and persistently stimulates Erk1/2, Akt, and signal transducer and activator of transcription 5 (Stat5). Of clinical interest, the inhibition of RAS farnesylation by tipifarnib decreases polyethylene-mera erythroid burst-forming unit hyperproliferation. During erythropoiesis, RAS is also regulated by newly emerging guanosine triphosphate (GTP)/guanosine diphosphate exchange factors. One is the Ras-GTPase activating protein Ras3, which when mutated in Scat mice leads to anemia and thrombocytopenia. A second is neurofibromin (Nf1), for which mutations have been associated with juvenile myelomonocytic leukemia, including anemia due to limited EPC differentiation.

**EPO/EPOR cytoprotective circuits**

EPO’s best-known effects are cytoprotective. Koulnis et al have described EPO’s slow yet persistent down-modulation of proapoptotic Bcl-2-like 11 (Bim) in murine splenic EPCs. Prior studies in HCD57 cells and primary murine EPCs also demonstrated EPO-induced Bim phosphorylation and proteasomal degradation. The inhibition of Bim therefore represents one EPO-induced EPC survival mechanism. Post-EPO dosing, Bcl-xL levels in splenic EPCs transiently increase, and in 32D-EPOR cells Bcl-xL is an EPO/EPOR/STAT5 target gene. These latter EPO effects, however, are not observed in erythroid colony-forming unit-like murine BM EPCs, and EPO can efficiently cytoprotect Bcl-xL−/− EPCs.

Important questions therefore arise concerning possible additional mediators of EPO/EPOR cytoprotection.
Via gene profiling of murine BM EPCs, an intracellular Spi2A serpin has been identified as a new EPO/EPOR/JAK2/Stat5 target, and cytotoxicity factor. Spi2A inhibits B- and L-cathepsins, which when leaked from damaged lysosomes can trigger apoptosis. Spi2A-KO mice exhibit compromised EPO-induced EPC formation, and worsened anemia due to hemolysis or irradiation. Spi2A further cytorects erythroblasts against ROS, an effect that is phenocopy by a cathepsin-B inhibitor. Pharmacologically, selective cathepsin inhibitors therefore might act to limit cell loss due to oxidant damage in thalassemia and/or sickle cell EPCs. During stress erythropoiesis, Fas ligand (FasL)/Fas levels can also substantially modulate murine splenic EPC survival. In human EPCs, tumor necrosis factor (TNF)-related apoptosis inducing ligand or TRAIL may be a more potent pro-apoptotic TNF, and FASL may support caspase-dependent late differentiation events. As further illustrated by recent gene profiling studies of human and murine EPCs, complexities can exist in erythroid regulator utilization among species (and erythroid tissues) that require reconciliation.

Additional emerging EPO response circuits

In the context of erythroid neoplasia, JAK2 hyperactivation due to a V617F mutation (within an inhibitory pseudokinase domain) is a frequently contributing factor. Polycythemia vera V617F EPCs can develop in the absence of EPO, although at lower efficiencies. Spi2A, a secreted TNF-related cytokine, ERFE has been discovered to act on hepatocytes to suppress hepcidin expression by EPCs, with the C1q/TNF cytokine family member erythrophoreine (ERFE/Ctrp-15) as a new example. Spi2A-KO mice exhibit compromised EPO-induced EPC formation, assemblas and/or sickle cell EPCs. During stress erythropoiesis, Fas ligand (FasL)/Fas levels can also substantially modulate murine splenic EPC survival. In human EPCs, tumor necrosis factor (TNF)-related apoptosis inducing ligand or TRAIL may be a more potent pro-apoptotic TNF, and FASL may support caspase-dependent late differentiation events. As further illustrated by recent gene profiling studies of human and murine EPCs, complexities can exist in erythroid regulator utilization among species (and erythroid tissues) that require reconciliation.

Figure 1 (continued)
exhibiting delayed recovery from blood-loss–induced anemia. By comparison, the disruption of ERFE in β-thalassemia mice diminishes iron overload. EPO modulation therefore has therapeutic potential for balancing systemic iron levels. Unexpectedly, EPO has also been shown to exert effects on pluripotent hematopoietic progenitor cells. Specifically, EPO at elevated levels can alter the transcriptomes of multi- and bi-potent progenitors. This generates lineage bias, and increases erythroid output while decreasing myelopoiesis. EPO therefore may guide EPC differentiation, as previously implicated in studies of EPO/EPOR-stimulated Akt phosphorylation of Gata1. Such EPO actions might contribute to rhEPO’s enhancement of erythroid recovery following allogeneic transplant.

**Summary**

Within EPO and EPOR circuits, important new components are being revealed. Several regulate endogenous EPO expression (Figure 1A). Apo-IRP1 inhibits Hif2α transcript translation, whereas iron reverses this effect, heightening HIF2α and EPO levels. Pharmacologically, PHD inhibitors that stabilize HIF2α can likewise increase EPO expression, as does acetate supplementation via enhancement of Hif2α acetylation during stress erythropoiesis.

Within EPCs, EPOR activity can be unexpectedly augmented by interactions with several plasma membrane proteins (Figure 1B). TRF2 acts via association with EPOR complexes, whereas Tfr1 is engaged upon p-IgA1 ligation, with each bolstering EPC formation. This ties two iron importers to EPO’s effects. In addition, the novel hEPC protein RHX associates with the hEPOR, enhances ERK1/2 activation, and supports erythroblast development.

Important downstream EPO signal transducers are also being discovered (Figure 1C). Within a central RAS/MEK module, these include MASL1, Rasa3, and neurofibrin, that act to balance ERK1/2 signaling and EPC production. For EPC cytoprotection, an EPO-induced Sp2A serpin and small molecule inhibitors of leached lysosomal cathepsins have emerged that lessen ROS-associated damage. Pro-erythropoietic actions of Akt, Ptc-γ1, and Src family kinases are also being more clearly defined. Finally, EPO is proving to exert guiding effects on early hematopoietic progenitors, pointing to new EPO target populations (and indicating an ability of EPO to affect cells harboring few EPORs). High merit therefore persists for continued investigations of novel EPO/EPOR action mechanisms.

**References**

22. Suzuki N, Hirano I, Pan X, Minegishi N, Yamamoto M. Erythropoietin production in neuroepithelial and neural crest cells during

**Acknowledgments**

This study was supported by grants from the National Institutes of Health National Heart, Lung, and Blood Institute grant R01 HL044491 and National Institute of Diabetes and Digestive and Kidney Diseases grant R01 DK089439 (D.M.W.) and National Heart, Lung, and Blood Institute grant F32 HL120596 (D.K.).

**Authorship**

Contribution: D.K. and D.M.W. contributed in substantial ways to review concepts and construction.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Don M. Wojchowski, Center of Excellence in Stem and Progenitor Cell Biology and Regenerative Medicine, Maine Medical Center Research Institute, 81 Research Drive, Scarborough, ME 04074; e-mail: wojchd@mmc.org.
37. Feng D, Kan YW. The binding of the ubiquitous
36. Zon LI, Youssoufian H, Mather C, Lodish HF, Orkin
35. Broudy VC, Lin N, Brice M, Nakamoto B,
34. Krishnan M, Nissenson AR. New alternatives in
42. Bulut GB, Sulahian R, Yao H, Huang LJ. Cbl
20. Haase VH. Regulation of erythropoiesis by hypoxia-
14. Bunn HF. Erythropoietin.
11. Papayannopoulou T. Erythropoietin receptor
30. Haase VH. Regulation of erythropoiesis by hypoxia-
39. Bulut GB, Sulahian R, Yao H, Huang LJ. Cbl
28. Bunn HF. Erythropoietin.
19. Yamaguchi Y, Hayashi A, Campagnoni CW, Kimura
16. Yamaguchi Y, Hayashi A, Campagnoni CW, Kimura
Emerging EPO and EPO receptor regulators and signal transducers

David Kuhrt and Don M. Wojchowski